Regulatory aspects of drug approval for macular degeneration-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Regulatory aspects of drug approval for macular degeneration

Published:2005-12-13 Issue:14 Volume:57 Page:2092-2098
ISSN:0169-409X
Container-title:Advanced Drug Delivery Reviews
language:en
Short-container-title:Advanced Drug Delivery Reviews

Author:

GRYZIEWICZ L

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiplexed In Vivo Screening Using Barcoded Aptamer Technology to Identify Oligonucleotide-Based Targeting Reagents;Nucleic Acid Therapeutics;2024-06-01

2. Biomaterials used for tissue engineering of barrier-forming cell monolayers in the eye;Frontiers in Bioengineering and Biotechnology;2023-09-27

3. Diverse applications and development of aptamer detection technology;Analytical Sciences;2023-09-13

4. Antiangiogenic therapy for ocular diseases: Current status and challenges;MedComm – Future Medicine;2023-02-08

5. Emerging innovations in nano-enabled therapy against age-related macular degeneration: A paradigm shift;International Journal of Pharmaceutics;2021-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP